Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT [0.03%]
基于EBMT慢性肿瘤工作组登记处资料的数十年间骨髓增生异常综合征移植变化趋势的研究
Marie Robin,Luuk Gras,Linda Koster et al.
Marie Robin et al.
Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial [0.03%]
移植组较常规治疗组镰状细胞病患者脑血管事件复合终点发生率更低：DREPAGREFFE试验结果
Francoise Bernaudin,Suzanne Verlhac,Elisabeth Ducros-Miralles et al.
Francoise Bernaudin et al.
Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard-care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE-1 (December 2010/June 2013), a French multic...
Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort [0.03%]
替西扎马布毒性的预防和免疫球蛋白替代疗法时机的全国队列研究
Astrid Hundebøll Torpe,Jonathan Thorsen,Gustav Mathiasen et al.
Astrid Hundebøll Torpe et al.
Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma" [0.03%]
对“改良综合疗法及首次玻璃体淋巴瘤治疗展望”的回应
Jing Gao,Li-Wei Lyu,Liang Wang
Jing Gao
Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group [0.03%]
初治KMT2A重排急性髓系白血病的临床特征及预后意义：ECLA多中心研究
Jiajia Pan,Chunmei Fu,Qing Ling et al.
Jiajia Pan et al.
Acute myeloid leukemia (AML) harboring KMT2A rearrangement (KMT2Ar) was generally associated with poor prognosis. We enrolled 490 patients with KMT2Ar from the East China Leukemia Alliance between March 2013 and August 2025. KMT2A::MLLT3 wa...
Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials [0.03%]
AL型淀粉样变性患者临床试验排除可测量疾病患者的共同门槛不当
Eugene Brailovski,Patrick Gould,Hani Hassoun et al.
Eugene Brailovski et al.
Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma" [0.03%]
对“改良综合治疗方案及明确原发玻璃体视网膜淋巴瘤未来发展方向”的回应
Asaad Trabolsi,Izidore S Lossos
Asaad Trabolsi
Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study [0.03%]
基于循环肿瘤DNA的外周T细胞淋巴瘤实时疗效评估与预后判断：一项前瞻性多中心队列研究
Zhao Donglu,Song Yuqin,Qin Jiayue et al.
Zhao Donglu et al.
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis [0.03%]
托拉喹莫德治疗复发/难治性多发性骨髓瘤的现实世界评估：国际骨髓工作组免疫疗法登记处的现实世界分析
Murali Janakiram,Carlyn R Tan,Hira Mian et al.
Murali Janakiram et al.
Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real-world study to comprehensively report muco-cutaneous toxicities, infections, and efficacy of talquetamab in ...